ImmuCell (ICCC) Q3 2026 earnings review
ImmuCell's sales jump 46%, but half go to one distributor
ImmuCell, maker of antibody products for calves, earned a profit, but one distributor took a bigger share of its sales. Sales rose 46%, helped by a weak quarter a year earlier, when distributors cut orders. Units that distributors resold to their customers climbed 18%, after 28% in the second quarter.
| Units distributors resold to customers | +18% +28% in the second quarter |
|---|---|
| Sales | $8.0M +46% from a year ago |
| Net income | $953,000 loss of $140,000 a year ago |
| Company outlook | No sales forecast $6.3M left to spend on factory expansion |
⚖️ Verdict: 🟢 Bullish
The story got better because ImmuCell earned its profit from selling calf products, not from a one-off settlement. Spending on Re-Tain, a cow udder treatment it dropped, has largely stopped. One caution: the top distributor's share of sales jumped to 52% from 41%, so some sales may be stock it bought ahead of winter.
The question now is whether farms are using more of the products or distributors are stocking up before the calving season. If farms are buying, distributor resales will keep up with ImmuCell's sales; if not, sales will slow early next year. Distributor resales during the winter peak will tell.
🐂 Bull Case
Sales Grew Across Every First Defense Product
First Defense is ImmuCell's line of antibody products that farmers give newborn calves by mouth to prevent scours, a deadly calf diarrhoea. "The expanded commercial team is delivering solid revenue growth," chief executive Olivier te Boekhorst said. The quarterly filing ties higher volumes to the sales push, "reflecting results from our sales team expansion".
The gains reached every product. In an October update, te Boekhorst said Tri-Shield, the premium version, grew 51%, while Dual-Force, popular with price-sensitive dairies, rose 36%. A newer feed line, a lower-cost formula for farms that feed calves in groups, added 37%.
- US sales: $6.9 million, up 29.2% from a year ago
- US sales in the same quarter a year earlier: up 2%, so the US base was not depressed
- Total sales against the same quarter two years ago: up about 34% by our math
This matters because a weak quarter a year ago flatters the total growth rate. US sales lacked that distortion, so they give the cleaner sign that new sales territories are winning farms.
What to watch: US sales growth in the fourth quarter, when the peak selling season begins. Growth near this quarter's pace would show the added territories bring new customers, not just a timing gain.
Profit Returned as Re-Tain Spending Disappeared
ImmuCell made an operating profit from its products this quarter. In the second quarter, a $2 million settlement over Re-Tain, a cow udder treatment it dropped, supplied all of it. Excluding that payment, operating margin reached 11.9% by our math, against below zero then.
The main change came below gross profit. Product development spending fell to 2.2% of sales from 12.6%, because Re-Tain work largely stopped. Sales and marketing took 2.6 percentage points less of sales, even with new hires.
- Gross margin: 44.2%, against 42.9% a year ago
- Old Re-Tain plant costs moved into cost of goods: about $0.4 million, or 5 percentage points of sales
- Gross margin without that shift: about 49% by our math
Finance chief Timothy Fiori credited "higher pricing and manufacturing execution" for the gross margin gain. The shift matters because ImmuCell now counts the idle plant's costs as factory costs. Gross margin will carry them until the plant makes First Defense, its calf antibody products.
What to watch: gross margin in the fourth quarter. The company blamed the second quarter's 33.9% on low output and scrapped materials, so a figure near this quarter's would show steadier production.
🐻 Bear Case
One Distributor Bought More Than Half of Sales
"Growth remained broad-based across our sales territories and product lines," said Bobbi Jo Brockmann, who runs sales and marketing. ImmuCell sells almost all its calf antibody products through distributors, which pass them on to farms.
One distributor, which the filing calls Company A, took a far larger share of sales. Brockmann also said the team was "encouraged by inventory levels heading into our peak season".
- Company A's share of sales: 52%, against 41% a year earlier
- Company A's purchases: up about 85% by our math
- Sales to all other customers: up about 19% by our math
- Company A's share of unpaid customer bills: 63%, against 45% in December
This matters because ImmuCell's own sales climbed far faster than the units distributors passed on. Higher prices explain part of that gap, but stock held by one distributor before winter may explain more. The filing warns that lower purchases by either of its two biggest distributors "could materially affect our revenues and liquidity".
What to watch: Company A's share of full-year sales in the annual report. A rising share while distributor resales slow would mean some third-quarter sales came out of the winter season.
Factory Expansion Will Use Most of the Cash
ImmuCell is converting its idle Re-Tain plant, built for a cow udder treatment it dropped, to make more First Defense calf antibodies. Chief executive Olivier te Boekhorst said the work is "projected to be completed on time and within budget".
- Expansion spending still to come: $6.3 million, within 15 months
- Cash at the end of September: $7.9 million, against $8.9 million in June
- Free cash flow this quarter: about minus $0.6 million by our math
Finance chief Timothy Fiori ended the share-sale program, citing "our strong cash position". But the remaining bill equals about 80% of cash on hand by our math. The filing also warns that the idle machines "may become obsolete".
What to watch: cash at year-end, once peak-season orders start. A balance below the remaining bill would leave ImmuCell relying on its credit line.
Settlement Brings CEO's Performance Option Within Reach
Administrative costs took 2.8 percentage points more of sales, and the filing blames higher executive pay. In January the board gave chief executive Olivier te Boekhorst a performance option. It vests only when four straight quarters of operating income reach triple the 2025 figure.
- Target: about $4.9 million of operating income, by our math
- Operating income so far in 2026: $4.86 million
- Of which the Re-Tain settlement: $2.0 million
The filing states that "the vesting of the option is probable". That matters because the settlement came from Re-Tain, a cow udder treatment ImmuCell dropped, not from the calf business. Counting it, a small fourth-quarter profit would vest the option by our math.
What to watch: the annual report's note on this option. It will show whether the board counted the settlement toward the target.
Risks this quarter didn't answer
Several concerns from earlier quarters got no clear answer in the release or the quarterly filing, so each one stands where it was before this report.
- Factory output: ImmuCell last gave monthly units for the first quarter; a new figure would show whether the second quarter's scrap problems are over.
- Market share: the latest share of treated US calves dates from the second quarter; a fresh figure would show whether new customers come from rivals.
- Repeat buyers: ImmuCell has not published how many customers stop buying; a figure would test whether farms lost during past shortages have returned.
- Sales outside the US: up 573% on a tiny base, but only 3.6% higher for the year so far; the year-end total will show whether Canada has recovered.
👓 Other Themes
ImmuCell Negotiates a $3 Million Bank Credit Line
Finance chief Timothy Fiori expects to sign a $3 million credit line with Maine Community Bank this quarter. It replaces a $1 million line that expired in September. The bank confirmed that ImmuCell meets all its loan terms. Its share-sale program, which let the company sell new stock into the market, closed with $6 million unused.
ImmuCell Stops Publishing Early Sales Figures
In October ImmuCell said it would "discontinue early sales reporting in the future", ending its habit of releasing sales weeks before full results. Management plans to report revenue only with the complete quarterly numbers. Investors lose an early read on the peak season, when quarterly sales swing most.
💲 Other KPIs
Inventory rose to $9.9 million from $9.1 million in June, as ImmuCell built stock for winter. Finished goods, products ready to ship, have grown 58% since December. Stock on hand now equals about 2.2 quarters of cost of goods sold, the highest of the last four quarters.
The share count behind profit per share grew 2.8% from a year ago. Employee options now count because the calf-health group earns a profit, and the board added executive grants in January. It sold no new shares this year, so options are now the main source of dilution.
Adjusted EBITDA, profit before interest, tax, depreciation and stock pay, reached $1.9 million, up 151% from a year ago. As a share of sales it climbed about ten percentage points. Because the measure leaves out stock pay, which rose more than fivefold, it flatters this quarter in particular.
🔮 Guidance
Unchanged. ImmuCell still plans a new freeze dryer and a bigger liquid processing line, finished by late 2027. The earlier plan totalled $8.0 million, so about $1.7 million is already spent by our math. Spread over a year, the rest equals about 19% of sales over the past year.
New. ImmuCell expects about $1.6 million of scheduled loan repayments this year, not counting any credit line. By our math, that leaves about $0.4 million for the fourth quarter, in line with the loan schedule. Repayments due in 2027 total about $1.2 million, the filing shows.
New. The finance team expects about $367,000 of interest this year, excluding amortised loan fees. By our math, that leaves about $89,000 for the fourth quarter, the same as the third. ImmuCell's debt all carries fixed rates, averaging 4.29%, so interest costs ease as loans shrink.
❓ Key Questions
Did distributors stock up before the winter season?
ImmuCell's sales jumped far faster than the units distributors resold, and one distributor's purchases nearly doubled. Management should say how many weeks of stock distributors now hold, against a year ago.
How many units does the plant make each month?
ImmuCell last gave monthly output for the first quarter, and the second quarter suffered scrap from bad purchased materials. A current figure would show whether the plant can meet peak demand before the expansion finishes.
Does the CEO's option target count the settlement?
Reported operating income includes the $2 million Re-Tain settlement. If the board counts it, a small fourth-quarter profit vests the option. Shareholders should know which figure the board uses.
Will the idle Re-Tain equipment need a write-down?
ImmuCell carries $11.8 million of idle Re-Tain assets, and the filing says some may become obsolete during the move. A write-down would cost no cash but would cut reported profit.
When could ImmuCell use its $4.9 million tax assets?
ImmuCell holds deferred tax assets, mostly past losses, with a full allowance against them. Steady profit could let it release that allowance as a one-time non-cash gain; readers need the test it applies.